Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 8,101–8,200 of 15,747
Butt, A. A., Peng, Y., Shaikh, O. S., Omer, S. B., Mayr, F., & Talisa, V. B. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad195 · Cited by 10
Oh, W., Jayaraman, P., Sawant, A. S., Chan, L., Levin, M. A., Charney, A. W., Kovatch, P., Glicksberg, B. S., & Nadkarni, G. N. (2021) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocab252 · Cited by 8
Zilbermint, M. F., Motevalli, M., Batty, K., Venner-Walcott, J., Edwards, A., Burley, T., Jackson, K., Akhtar, M., & Demidowich, A. P. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110898 · Cited by 9
Cheruvu, N. P. S., van Duijn, E., Spigt, P. A., Barbu, I., Toussi, S. S., Schildknegt, K., Jones, R., & Obach, R. S. (2023) · Drug Metabolism and Disposition · doi:10.1124/dmd.123.001416 · Cited by 7
Short-Term Drop in Antibody Titer after the Third Dose of SARS-CoV-2 BNT162b2 Vaccine in Adults
Herzberg, J., Fischer, B., Becher, H., Becker, A., Honarpisheh, H., Guraya, S. Y., Strate, T. G., & Knabbe, C. (2022) · Vaccines · doi:10.3390/vaccines10050805 · Cited by 8
“The protective role of SARS-CoV-2 BNT162b2 vaccine, as introduced by BioNTech/Pfizer, has been endorsed by several studies[1,2].”
BackgroundVaccine-elicited B- and T-cell immunity to SARS-CoV-2 is impaired in chronic lung disease patients
Liu, H., Aviszus, K., Zelarney, P. T., Liao, S., Gerber, A. N., Make, B. J., Wechsler, M. E., Marrack, P., & Reinhardt, R. L. (2023) · ERJ Open Research · doi:10.1183/23120541.00400-2023 · Cited by 7
Hussain, M., Amanullah, A., Aslam, A., Raza, F., Arzoo, S., Qureshi, I. W., Waheed, H., Jabeen, N., Shabbir, S., Sayeed, M. A., et al. (2022) · Polymers · doi:10.3390/polym14163263 · Cited by 8
“So far, against SARS-CoV-2, two mRNA-based vaccines, BNT162b2 and mRNA-1273, have been developed by Pfizer and Moderna, respectively [1,3].”
BackgroundA review of approved COVID-19 vaccines
Jamkhande, A., Khairnar, M., Gavali, N., Patil, Y. B., Kapare, S. S., & Bhosale, K. P. (2021) · Roczniki Państwowego Zakładu Higieny · doi:10.32394/rpzh.2021.0177 · Cited by 8
COVID-19 Rekindling Herpes Zoster in an Immunocompetent Patient
Puri, P., Parnami, P., Athwal, P. S. S., Kumari, S., Kumar, C., & Suri, Y. (2021) · Cureus · doi:10.7759/cureus.18049 · Cited by 9
“Vaccine trials do not include the person-time to estimate the incidence of rare events [16].”
Gastroparesis After Pfizer-BioNTech COVID-19 Vaccination
Scott, J., Anderson, J., Mallak, N., Beitinjaneh, B., Wei, K. S., & Otaki, F. A. (2021) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001354 · Cited by 7
A Bullous Eruption following the Pfizer‐BioNTech COVID‐19 vaccination
D’Cruz, A., Parker, H., & Saha, M. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.17606 · Cited by 7
Ankunda, V., Katende, J. S., Oluka, G. K., Sembera, J., Baine, C., Odoch, G., Ejou, P., Kato, L., The COVID-19 Immunoprofiling Team, Kaleebu, P., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1325387 · Cited by 7
SARS-CoV-2 transmission in a highly vulnerable population of Brazil: a household cohort study
Coelho, L. E., Luz, P. M., Castanheira, D., Jalil, E. M., Perazzo, H., Torres, T. S., Cardoso, S. W., Peixoto, E. M., Nazer, S., Massad, E., et al. (2024) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2024.100824 · Cited by 13
Song, Y., Xu, T., Li, H., Liu, J., Cao, S., Yang, Y., Li, N., Lv, P., Han, M., Sun, H., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113811 · Cited by 10
Effect of booster vaccination against Delta and Omicron SARS-CoV-2 variants in Iceland
Norddahl, G. L., Melsted, P., Gunnarsdóttir, K., Halldorsson, G. H., Olafsdottir, T. A., Gylfason, A., Kristjánsson, M., Magnússon, Ó. Þ., Sulem, P., Gudbjartsson, D. F., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33076-4 · Cited by 8
Gao, J., Lun, P., Ding, Y. Y., & George, P. P. (2022) · The Journal of Frailty & Aging · doi:10.14283/jfa.2022.12 · Cited by 7
“Participants included in the trials for three vaccines (Pfizer-BioNTech, Moderna, and Sputnik V) were generally healthy or had chronic comorbidities such as diabetes, obesity, or heart disease (8, 9, 24).”
BackgroundMutnal, M. B., Johnson, S., Mohamed, N., Abddelgader, R., Morales, L., Volz, M., Walker, K., Arroliga, A. C., & Rao, A. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27373 · Cited by 7
Taşkaldıran, I., Altay, F. P., Bozkuş, Y., İyidir, Ö. T., Nar, A., & Tütüncü, N. B. (2022) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530322666220616104058 · Cited by 7
When might host heterogeneity drive the evolution of asymptomatic, pandemic coronaviruses?
Okamoto, K. W., Ong, V., Wallace, R. G., Wallace, R., & Chaves, L. F. (2022) · Nonlinear Dynamics · doi:10.1007/s11071-022-07548-7 · Cited by 8
Bloise, S., Marcellino, A., Frasacco, B., Gizzone, P., Ciolli, C. P., Martucci, V., Sanseviero, M., Giudice, E. D., Ventriglia, F., & Lubrano, R. (2022) · Vaccines · doi:10.3390/vaccines10081224 · Cited by 8
Developing standard safety outcomes for COVID-19 vaccines
Buttery, J. P. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.03.004 · Cited by 7
COVID-19 after two doses of mRNA vaccines in kidney transplant recipients
Mehta, R. B., & Silveira, F. P. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16778 · Cited by 8
Biswas, S., Mahmud, S., Mita, M. A., Afrose, S., Hasan, M. R., Paul, G. K., Shimu, M. S. S., Uddin, M. S., Zaman, S., Park, M. N., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.825245 · Cited by 6
Efectividad de la vacuna BNT162b2 para prevenir la COVID-19 en personal sanitario
Chico-Sánchez, P., Gras-Valentí, P., Algado-Sellés, N., Merino, E., Rodrı́guez, J. C., Ronda, E., & Sánchez–Payá, J. (2021) · Gaceta Sanitaria · doi:10.1016/j.gaceta.2021.11.003 · Cited by 7
Zhu, J., Sha, J., Batra, H., Jain, S., Wu, X., Hendrix, E. K., Kilgore, P. B., Sun, K., Plante, K. S., Plante, J. A., et al. (2025) · Small Science · doi:10.1002/smsc.202400580 · Cited by 7
Assessing Menstrual Changes Among Young Indian Females Post-SARS-CoV-2 Vaccination
Tandon, A., Kumar, N., Aggarwal, S., Anjana, Y., SACHDEVA, M. P., Gupta, V., & Kumar, G. T. (2023) · Cureus · doi:10.7759/cureus.50025 · Cited by 9
“However, the potential impact of SARS-CoV-2 vaccines on the menstrual cycle was not initially documented as a recognized side effect, despite anecdotal reports from a subset of women who shared their experiences on social media [9,10,14,15].”
BackgroundAlwani, S., Rai, R., Zittlau, I. C., Rekve, J., Michel, D. L., & Badea, I. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091794 · Cited by 8
A Randomized Clinical Trial of a Fractional Low Dose of BNT162b2 Booster in Adults Following AZD1222
Nantanee, R., Jantarabenjakul, W., Jaru-Ampornpan, P., Sodsai, P., Himananto, O., Athipunjapong, J., Sophonphan, J., Nanthapisal, S., Hirankarn, N., & Puthanakit, T. (2022) · Vaccines · doi:10.3390/vaccines10060914 · Cited by 9
“, headache, fatigue, myalgia, and arthralgia [13].”
BackgroundResultVaccination for COVID-19: Is it important and what should you know about it?
Wu, C.-P., Adhi, F., & Culver, D. A. (2021) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.88a.ccc076 · Cited by 8
Studying SARS-CoV-2 interactions using phage-displayed receptor binding domain as a model protein
Pérez-Massón, B., Quintana-Perez, Y., Tundidor, Y., Pérez‐Martínez, D., Castro-Martínez, C., Pupo-Meriño, M., Orosa-Vázquez, I., Relova-Hernández, E., Villegas, R., Guirola, O., et al. (2024) · Scientific Reports · doi:10.1038/s41598-023-50450-4 · Cited by 6
Aiano, F., Ireland, G., Powell, A. A., Campbell, C., Judd, A., Davies, B., Saib, A., Mangtani, P., Nguipdop‐Djomo, P., SIS Study Group, et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2023-071707 · Cited by 7
Gallego‐Valcarce, E., Shabaka, A., León-Póo, M., Gruss, E., Acedo, J. M., Cordon, A., Cases‐Corona, C., & Juarez, G. M. F. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.927546 · Cited by 7
Severe acute respiratory syndrome (SARS)
Beltz, L. A. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-98809-4.00004-8 · Cited by 7
Zhang, S., Bi, G., Wang, X., Yang, Y., Qi, J., Li, S., Mao, X., Peng, R., & Yang, P. (2021) · medRxiv · doi:10.1101/2021.03.10.21252748 · Cited by 7
Esen, M., Fischer-Herr, J., Gabor, J. J., Gaile, M., Fleischmann, W. A., Smeenk, G. W., de Moraes, R. A., Bélard, S., Calle, C. L., Woldearegai, T. G., et al. (2024) · Vaccines · doi:10.3390/vaccines12111288 · Cited by 9
Gil-Manso, S., Carbonell, D., Pérez-Fernández, V. A., López-Esteban, R., Alonso, R., Muñóz, P., Ochando, J., Sánchez-Arcilla, I., Bellón, J. M., Correa‐Rocha, R., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10071676 · Cited by 8
“1% for the mRNA-1273 vaccine [10] and 95% for the BNT162b2 vaccine [5].”
BackgroundIdentifying US Counties with High Cumulative COVID-19 Burden and Their CharacteristicsPreprint
Li, D., Gaynor, S. M., Quick, C., Chen, J. T., Stephenson, B., Coull, B. A., & Lin, X. (2020) · medRxiv · doi:10.1101/2020.12.02.20234989 · Cited by 6
Bagno, F. F., Andrade, L. A. F., Sérgio, S. A. R., Parise, P. L., de Toledo-Teixeira, D. A., Gazzinelli, R. T., Fernandes, A. P., Teixeira, S. M. R., Granja, F., Proença‐Módena, J. L., et al. (2022) · Viruses · doi:10.3390/v14030510 · Cited by 7
“[3] Viral vectors have also been extensively used in the vaccine rollout.”
BackgroundZhu, J. S., Wang, Q., & Huang, M. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1129183 · Cited by 8
Jain, A., Prajapati, S. K., Tripathi, M., Raichur, A. M., & Kanwar, J. R. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1909473 · Cited by 7
Protection against SARS-CoV-2 Beta Variant in mRNA-1273 Boosted Nonhuman PrimatesPreprint
Corbett, K. S., Gagné, M., Wagner, D. A., Connell, S. O., Narpala, S., Flebbe, D. R., Andrew, S. F., Davis, R. L., Flynn, B. J., Johnston, T. S., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.11.456015 · Cited by 9
Post‐COVID ‐19 vaccination arm pain diagnosed as complex regional pain syndrome: A case report
Cho, J. H., Ahn, H.-C., & Choi, Y. (2022) · Pain Practice · doi:10.1111/papr.13177 · Cited by 7
Single-dose SARS-CoV-2 vaccine in a prospective cohort of COVID-19 patientsPreprint
van Gils, M. V., van Willigen, H. V., Wynberg, E., Han, A., van der Straten, K., Verveen, A., Lebbink, R., Dijkstra, M., Burger, J., Oomen, M., et al. (2021) · medRxiv · doi:10.1101/2021.05.25.21257797 · Cited by 10
Piening, A., Ebert, E. C., Khojandi, N., Alspach, E., & Teague, R. M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1022732 · Cited by 7
“Fortunately, the development of efficacious vaccines has been successful in preventing severe infection in the majority of vaccinated individuals (2, 3).”
BackgroundThe potential risks of delaying the second vaccine dose during the SARS-CoV-2 pandemic
Humphreys, I. R., & Godkin, A. J. (2021) · QJM · doi:10.1093/qjmed/hcab046 · Cited by 6
Nanotechnology strategies for endometrium health: Are we on the right track?
Herrara, V., Tarab‐Ravski, D., Chauhan, S. C., Narang, N., Islam, M. M., Peer, D., Prasad, R., & Yallapu, M. M. (2025) · Bioactive Materials · doi:10.1016/j.bioactmat.2025.08.016 · Cited by 18
Tortora, F., Civita, E. L., Trivedi, P., Febbraio, F., Terracciano, D., & Cimmino, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054601 · Cited by 8
Silva, F. M., Duarte‐Mendes, P., Ferreira, J. P., Carvalho, E., Monteiro, D., Massart, A. G. M., Farinha, C. M. N., Soares, C., & Teixeira, A. M. (2024) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0000000000003510 · Cited by 8
“On the one hand, either adenovirus-vector or mRNA vaccines cause high concentrations of neutralizing antibodies to avoid cytokine dysregulation (68,69).”
On the safety and effectiveness of COVID-19 vaccines, certainties and uncertainties
Escola Nacional de Saúde Pública Sérgio Arouca, F. O. C. (., de Oliveira, A. C. A. X., Delgado, I. F., Instituto Nacional de Controle de Qualidade em Saúde, F. O. C. (., Paumgartten, F. J. R., & Escola Nacional de Saúde Pública Sérgio Arouca, F. O. C. (. (2021) · doi:10.22239/2317-269x.01881 · Cited by 7
Ocular Implications of COVID-19 Infection and Vaccine-Related Adverse Events
Parmar, U. P. S., Surico, P. L., Singh, R. B., Musa, M., Scarabosio, A., Surico, G., Maniaci, A., Lavalle, S., D’Esposito, F., Longo, A., et al. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14080780 · Cited by 11
Zhou, F., Vahokoski, J., Øyen, S., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-00817-z · Cited by 7
Dabas, R., Navaratnam, N., Iino, H., Saidjalolov, S., Matile, S., Carling, D., Rueda, D., & Kamaly, N. (2024) · Materials Today Bio · doi:10.1016/j.mtbio.2024.101425 · Cited by 14
Khan, S., Hosseinian, S., Assis, R., Khalil, G., Luu, M., Jain, A., Horváth, P., Nakajima, R., Palma, A., Hoang, A., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1166261 · Cited by 7
“Both vaccines provide high rates of protective efficacy of up to 95% against the targeted virus strain following two doses administered at least 3-4 weeks apart (1, 2).”
BackgroundInfluentialArora, P., Kempf, A. M., Nehlmeier, I., Graichen, L., Winkler, M. S., Lier, M., Schulz, S. R., Jäck, H., Cossmann, A., Stankov, M. V., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110754 · Cited by 8
“At present, vaccination represents our main weapon to combat the COVID-19 pandemic, with several vaccines being avail- This is an open access article und able (Baden et al., 2021; Jara et al., 2021; Polack et al., 2020; Sadoff et al., 2021; Voysey et al., 2021).”
Wang, R., Wang, J., Hu, T., & Zhou, X. (2022) · Vaccines · doi:10.3390/vaccines10050726 · Cited by 7
Stiving, A. Q., Foreman, D. J., VanAernum, Z. L., Dürr, E., Wang, S., Vlasak, J., Galli, J. D., Kafader, J. O., Tsukidate, T., Li, X., et al. (2023) · Journal of the American Society for Mass Spectrometry · doi:10.1021/jasms.3c00309 · Cited by 8
Knottnerus, J. A. (2021) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2021.03.006 · Cited by 8
Nappi, F., Iervolino, A., & Singh, S. (2022) · Biomedicines · doi:10.3390/biomedicines10020437 · Cited by 9
Bonnet, B., Chabrolles, H., Archimbaud, C., Brebion, A., Godignon, M., Dutheil, F., Lambert, C., Cosme, J., Mirand, A., Ollier, A., et al. (2022) · Journal of Infection · doi:10.1016/j.jinf.2022.03.006 · Cited by 6
Vaccination and variants: Retrospective model for the evolution of Covid-19 in Italy
Fierro, A., Romano, S., & Liccardo, A. (2022) · PLoS ONE · doi:10.1371/journal.pone.0265159 · Cited by 11
Akhtar, N., Mishra, R., Tripathi, S., Rendón-Marín, S., Rao, M. P. N., Orduz, A. F. C., Magdaleno, J. S. L., Shaikh, A. R., Ruíz-Saenz, J., Cavallo, L., et al. (2025) · Frontiers in Veterinary Science · doi:10.3389/fvets.2025.1665999 · Cited by 11
Lim, S., Lee, Y., Kim, D. W., Park, W. S., Yoon, J. H., & Lee, J. Y. (2022) · Infection and Chemotherapy · doi:10.3947/ic.2022.0009 · Cited by 7
ANCA-Associated Vasculitis after Moderna COVID-19 Vaccination
Gen, S., Iwai, T., Ohnari, S., Nobe, K., & Ikeda, N. (2023) · Case Reports in Nephrology · doi:10.1155/2023/4906876 · Cited by 9
Castillo, L. A., Fernández-Niño, J. A., Rojas-Botero, M. L., Palacios-Clavijo, A. F., Pedraza, M. G., Rincón, L. E., Pinto-Álvarez, M., Gómez, F. R., & Valdivia, B. T. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3944059 · Cited by 8
CRISPR technology in human diseases
Feng, Q., Li, Q., Zhou, H., Wang, Z., Lin, C., Jiang, Z., Liu, T., & Wang, D. (2024) · MedComm · doi:10.1002/mco2.672 · Cited by 11
Magalis, B. R., Rich, S. N., Tagliamonte, M. S., Mavian, C. N., Cash, M. N., Riva, A., Marini, S., Amador, D. M., Zhang, Y., Shapiro, J., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac197 · Cited by 7
“6% protection against severe disease [6], whereas the Moderna (mRNA-1273) vaccine conferred 94.”
BackgroundKoletzko, S., Thi, T. G. L., Zhelyazkova, A., Osterman, A., Wichert, S. P., Breiteneicher, S., Koletzko, L., Schwerd, T., Völk, S., Jebrini, T., et al. (2023) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01170-6 · Cited by 6
“Controlled pivotal trials of COVID-19 vaccine efficacy do not fully reflect the extent of differential vaccine responses in the general population [17, 18] because they exclude participants above a certain age and those with underlying diseases.”
BackgroundLombardi, A., Renisi, G., Consonni, D., Oggioni, M., Bono, P., Renteria, S. U., Piatti, A., Pesatori, A. C., Castaldi, S., Muscatello, A., et al. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07083-1 · Cited by 7
“The absence of important symptoms is a reassuring finding, which confirms the data about the efficacy of the BNT162b2 vaccine in preventing the severe form of COVID-19 reported in the registration study [6].”
ResultInflammatory Arthritis Associated with COVID-19 Vaccination
Mung, S. M., Goh, T. L., Hughes, M. J., et al. (2023) · Cureus · doi:10.7759/cureus.35951 · Cited by 7
“A two-dose regime of COVID-19 vaccine has been reported to have efficacy of up to 95% in preventing symptomatic COVID-19 among adults who are aged 16 years and above [4,5].”
BackgroundImmordino, P., Pisciotta, V., Amodio, E., Bonura, C., Bonura, F., Cacioppo, F., Calamusa, G., Capra, G., Casuccio, A., Grazia, S. D., et al. (2023) · Vaccines · doi:10.3390/vaccines11111702 · Cited by 8
Wang, R., Mathes, S., Claussen, C., Biedermann, T., & Brockow, K. (2023) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.14987 · Cited by 8
Herpes zoster ophthalmicus in two women after Pfizer–BioNTech (BNT162b2) vaccine
Bernardini, N., Skroza, N., Mambrin, A., Proietti, I., Marchesiello, A., Marraffa, F., Rossi, G., Volpe, S., Tolino, E., & Potenza, C. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27366 · Cited by 7
“It has been shown to be safe and effective by conferring 95% protection against COVID‐19.(1) However, there are few adverse events; the most described are pain at the injection site, fatigue, and headache.”
BackgroundInfluentialEl-Menyar, A. A., Khan, N. A., Mekkodathil, A. A., Rizoli, S. B., Consunji, R. J., Elmenyar, E., Galwankar, S. C., & Al-Thani, H. A. S. (2022) · Medicine · doi:10.1097/md.0000000000030609 · Cited by 7
Colomer, M. À., Margalida, A., Alòs, F., Oliva‐Vidal, P., Vilella, A., & Fraile, L. J. (2021) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2021.147816 · Cited by 7
“(Polack et al., 2020; Knoll and Wonodi, 2020).”
Profiling patent compounds in lipid nanoparticle formulations of siRNA
Han, Y., Wang, M., Chen, Y., Ouyang, D., Zheng, Y., & Yuanjia, H. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102362 · Cited by 10
Garvey, M. I., Wilkinson, M. A. C., Holden, E., et al. (2021) · Journal of Infection · doi:10.1016/j.jinf.2021.04.027 · Cited by 7
Evolving SARS-CoV-2 Vaccines: From Current Solutions to Broad-Spectrum Protection
Qiao, R., Li, J., Gong, J., Shao, Y., Yu, J., Chen, Y., Lu, Y., Yang, L., Lin, L., Hu, Z., et al. (2025) · Vaccines · doi:10.3390/vaccines13060635 · Cited by 10
“In Phase III trials, BNT162b2 demonstrated 95% efficacy against symptomatic COVID-19 [81].”
Multisystem Inflammatory Syndrome (MIS) following SARS-CoV-2 vaccinations; a systematic review
Elsaid, M., Nune, A., Hesham, D., et al. (2023) · Tropical Diseases Travel Medicine and Vaccines · doi:10.1186/s40794-023-00204-x · Cited by 7
“SARS-CoV-2 vaccines are generally safe and play a critical role in disease prevention by reducing the severity and spread of COVID-19 [2, 3].”
BackgroundConfidence interval estimation for vaccine efficacy against COVID-19
Wei, Q., Wang, P., & Yin, P. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.848120 · Cited by 7
Pardo, I., Maezato, A. M., Callado, G. Y., Gutfreund, M. C., Hsieh, M. K., Lin, V., Kobayashi, T., Salinas, J. L., Subramanian, A. K., Edmond, M. B., et al. (2024) · Antimicrobial Stewardship & Healthcare Epidemiology · doi:10.1017/ash.2024.369 · Cited by 6
Lee, Y. J., Kim, S., Park, Y. E., Chang, J. Y., Song, H. J., Kim, D. H., Yang, Y. J., Kim, B. C., Lee, J. G., Yang, H. C., et al. (2021) · Korean Journal of Gastroenterology · doi:10.4166/kjg.2021.110 · Cited by 7
Bhella, S., Wilkin, A. M., Hueniken, K., Vijenthira, A., Sébag, M., Wang, P., Hicks, L. K., Hay, A. E., Assouline, S., Fraser, G., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.06.041 · Cited by 9
A scientometrics study of the nanomedicines assisted in respiratory diseases
Yang, Y., Luo, D., Inam, M., Hu, J., Zhou, Y., Xu, C., & Chen, W. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.1053653 · Cited by 11
“The results indicated for the highest cited document, Polack verified the safety and efficacy of the COVID-19 vaccine produced by BioNTech and Pfizer (Polack et al., 2020).”
ResultPerceived COVID-19 vaccine attributes associated with early adoption among adults in rural Indiana
Hunter‐Mullis, K., Macy, J. T., Greene, A. R., & Simon, K. I. (2022) · Health Education Research · doi:10.1093/her/cyac029 · Cited by 7
“for COVID-19-associated hospitalization, postCOVID-19 conditions and deaths [9, 10, 11].”
BackgroundBNT162b2 COVID-19 Vaccines in Children, Adolescents and Young Adults with Cancer—A 1-Year Follow-Up
Donzé, C., Min, V., Ninove, L., de Lamballerie, X. N., Revon‐Rivière, G., Verschuur, A. C., Saultier, P., & André, N. (2023) · Vaccines · doi:10.3390/vaccines11050989 · Cited by 7
“BNT162b2 vaccine is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion-stabilized, membrane-anchored SARS-CoV-2 full-length spike protein [14].”
BackgroundThe impact of coronavirus disease 2019 on people with HIV
del Amo, J., Diaz, A., & Polo, R. (2021) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000799 · Cited by 9
SARS-CoV-2-Übertragungswege und Implikationen für den Selbst- und Fremdschutz
Oh, D., Böttcher, S., Kröger, S., & von Kleist, M. (2021) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-021-03389-8 · Cited by 16
Cardoso, S., de Sousa, F. P., Filho, P. D. A. P., & Azzoni, A. R. (2022) · Molecular Biology Reports · doi:10.1007/s11033-022-07239-x · Cited by 7
“Messenger RNA vaccines have recently demonstrated high efficacy at preventing Covid-19 illness [1, 2], and are currently being used globally.”
BackgroundBurhamah, W., Alkhayyat, A., Oroszlányová, M., AlKenane, A., Jafar, H., Behbehani, M., & Almansouri, A. (2021) · Cureus · doi:10.7759/cureus.16261 · Cited by 7
“On December 11, 2020, the United States Food and Drug Administration (FDA) issued an emergency use authorization for the Pfizer-BioNTech COVID-19 vaccine [5], and only a week later, the Moderna COVID-19 vaccine received emergency use authorization [6].”
Sakr, M. M., Elsayed, N. S., & El-Housseiny, G. S. (2021) · Microbial Pathogenesis · doi:10.1016/j.micpath.2021.104809 · Cited by 9
Nishioka, K., Yamaguchi, S., Yasuda, I., Yoshimoto, N., Kojima, D., Kaneko, K., Aso, M., Nagasaka, T., Yoshida, E., Uchiyama, K., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.874831 · Cited by 7
“Besides the common adverse events following COVID-19 mRNA vaccination, including injection site reactions, fever, fatigue, headaches, and muscle pain (2), rare but severe adverse reactions such as anaphylaxis and myocarditis have been reported (3–5).”
BackgroundInfluentialMarconi, E., Crescioli, G., Bonaiuti, R., Pugliese, L., Santi, R., Nesi, G., Cerbai, E., Vannacci, A., & Lombardi, N. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15421 · Cited by 7
“Clinical trials have shown that most COVID-19 vaccines are efficacious, with a satisfactory safety profile.(6) Trials on the Pfizer-BioNTech vaccine have revealed a mild imbalance between vaccinated and placebo groups with respect to the number of cases of hypersensitivity”
BackgroundKaufmann, C. C., Villatore, A., HEUGL, M., Kvakan, H., Zweiker, D., Sala, S., Mazzone, P., Huber, K., & Peretto, G. (2023) · Minerva Cardiology and Angiology · doi:10.23736/s2724-5683.22.06204-4 · Cited by 8
Welbourne, E. N., Copley, R. J., Owen, G. R., Evans, C. A., Isoko, K., Cook, K., Cordiner, J., Kis, Z., Moghadam, P. Z., & Dickman, M. J. (2025) · The Analyst · doi:10.1039/d5an00033e · Cited by 11
Advancing ORFV‐Based Therapeutics to the Clinical Stage
Helmold, M., & Amann, R. (2025) · Reviews in Medical Virology · doi:10.1002/rmv.70038 · Cited by 8
“Solicited systemic reactions were more common among younger participants than older ones, consistent with reports from other COVID‐19 vaccine studies [137, 138].”
Modified mRNA-Based Vaccines Against Coronavirus Disease 2019
Wang, A. Y. L. (2022) · Cell Transplantation · doi:10.1177/09636897221090259 · Cited by 8
Akaishi, T., Onodera, T., Takahashi, T., Harigae, H., & Ishii, T. (2023) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.2023.j002 · Cited by 7
Delivering the Message: Translating mRNA Therapy for Liver Inherited Metabolic Diseases
Gurung, S., Perocheau, D. P. B., Ghosh, R., Hart, S. L., & Baruteau, J. (2025) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.70078 · Cited by 11
“Uplifted by the unprecedented success of mRNA vaccines against severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2), mRNA-based therapeutics have demonstrated their groundbreaking ability to act as an efficacious and safe technology platform for human use [8, 9].”
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.